- Home
- DAL vs ALNY Comparison
DAL vs ALNY Comparison
Compare DAL & ALNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DAL | ALNY |
|---|---|---|
| Founded | 1924 | 2002 |
| Country | United States | United States |
| Employees | 78400 | 115 |
| Industry | Air Freight/Delivery Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 38.2B | 40.8B |
| IPO Year | 2004 | 2004 |
Fundamental Metrics
Financial Performance| Metric | DAL | ALNY |
|---|---|---|
| Price | $73.23 | $295.00 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 19 | 28 |
| Target Price | $79.26 | ★ $471.00 |
| AVG Volume (30 Days) | ★ 8.1M | 1.0M |
| Earning Date | 04-08-2026 | 04-30-2026 |
| Dividend Yield | ★ 1.13% | N/A |
| EPS Growth | 43.71 | ★ 206.88 |
| EPS | N/A | ★ 2.33 |
| Revenue | ★ $41,244,000,000.00 | $1,037,418,000.00 |
| Revenue This Year | $3.47 | $52.67 |
| Revenue Next Year | $3.97 | $31.48 |
| P/E Ratio | ★ N/A | $126.72 |
| Revenue Growth | N/A | ★ 22.88 |
| 52 Week Low | $45.28 | $284.19 |
| 52 Week High | $76.39 | $495.55 |
Technical Indicators
Market Signals| Indicator | DAL | ALNY |
|---|---|---|
| Relative Strength Index (RSI) | 63.02 | 39.47 |
| Support Level | $56.05 | $287.00 |
| Resistance Level | $73.24 | $322.26 |
| Average True Range (ATR) | 2.07 | 10.27 |
| MACD | 0.40 | -0.85 |
| Stochastic Oscillator | 79.19 | 26.85 |
Price Performance
Historical ComparisonAbout DAL Delta Air Lines Inc.
Atlanta-based Delta Air Lines is one of the world's largest airlines, with a network of over 300 destinations in more than 50 countries. Delta operates a hub-and-spoke network, where it gathers and distributes passengers across the globe through its biggest hubs in Atlanta, New York, Salt Lake City, Detroit, Seattle, and Minneapolis-St. Paul. Delta has historically earned most of its international revenue and profits from flying passengers over the Atlantic Ocean.
About ALNY Alnylam Pharmaceuticals Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam's commercial RNAi therapeutic products include Onpattro and Amvuttra (for hATTR amyloidosis), Givlaari (for acute hepatic porphyria), and Oxlumo (for primary hyperoxaluria type 1), all developed and commercialized by Alnylam. Plus, Leqvio (for hypercholesterolemia) and Qfitlia (for hemophilia A or B), which are being commercialized by Alnylam's partners, Novartis and Sanofi, respectively. It also has several clinical programs across various therapeutic areas, including cardio-metabolic diseases, neuroscience, and hematology.